REVIEW

Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing

Marta Herreros-Villanueva a,b,*, Luis Bujanda b,c, Lourdes Ruiz-Rebollo d, Rosana Torremocha e, Ricardo Ramos e, Rubén Martín a, María Consuelo Artigas a

a Facultad de Ciencias de la Salud, Universidad Isabel I, Burgos, Spain
b Department of Gastroenterology, Hospital Donostia/Instituto Biodonostia, San Sebastián, Spain
c Department of Gastroenterology, Hospital Donostia/Instituto Biodonostia, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco UPV/EHU, San Sebastián, Spain
d Department of Gastroenterology, Hospital Clínico de Valladolid, Valladolid, Spain
e Genomics Unit, Scientific Park, Madrid, Spain

Received 21 October 2021; accepted 29 December 2021

KEYWORDS
Liquid biopsy; KRAS; Mutation; Pancreatic cancer; Next generation sequencing; Target therapy

Abstract
Background: Pancreatic cancer remains one of the most devastating malignancies due to the absence of techniques for early diagnosis and the lack of target therapeutic options for advanced disease. Next Generation Sequencing (NGS) generates high throughput and valuable genetic information when evaluating circulating tumor DNA (ctDNA); however clinical utility of liquid biopsy in pancreatic cancer has not been demonstrated yet.

The aim of this study was to evaluate whether results from a Next Generation Sequencing panel on plasma samples from pancreatic cancer patients could have a clinical significance.

Methods: From December 2016 to January 2020, plasma samples from 27 patients with pancreatic ductal adenocarcinoma at two different tertiary Spanish Hospitals underwent ctDNA testing using a commercial NGS panel of 65 genes. Clinical data were available for these patients. VarsSome Clinical software was used to analyse NGS data and establish pathogenicity.

Results: Evaluable NGS results were obtained in 18 out of the 27 plasma samples. Somatic pathogenic mutations were found mainly in KRAS, BRCA2, FLT3 and HNF1A, genes. Pathogenic mutations were detected in 50% of plasma samples from patient diagnosed at stages III-IV samples. FLT3 mutations were observed in 22.22% of samples which constitute a novel result in the field.

* Corresponding author.
E-mail address: martahv1978@hotmail.com (M. Herreros-Villanueva).

0210-5705/© 2022 Elsevier España, S.L.U. All rights reserved.

Please cite this article as: M. Herreros-Villanueva, L. Bujanda, L. Ruiz-Rebollo et al., Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing, Gastroenterología y Hepatología, https://doi.org/10.1016/j.gastrohep.2021.12.011